Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries BiomX Presenting at Three Upcoming Investor Conferences By: BiomX Inc. via Business Wire February 24, 2022 at 08:00 AM EST 2022 Aegis Virtual Conference on February 24, 2022 Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022 BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022. 2022 Aegis Virtual Conference – February 23-25, 2022 Date & Time: Thursday, March 24, 2:30 PM EST Presenter: Jonathan Solomon Conference registration: Link Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022 Date & Time: Tuesday, March 1, 8:30 AM EST Presenter: Conference registration: Jonathon Solomon Link Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022 Date & Time: Thursday, March 17, 2:00 PM EST Presenter: Jonathan Solomon Conference registration: Link Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website. About BiomX Inc. BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005117/en/Contacts BiomX Contacts Investor Relations: LifeSci Advisors, LLC John Mullaly (617)-698-9253 jmullaly@lifesciadvisors.com BiomX, Inc. Anat Primovich Corporate Project Manager +972 (50) 697-7228 anatp@biomx.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
BiomX Presenting at Three Upcoming Investor Conferences By: BiomX Inc. via Business Wire February 24, 2022 at 08:00 AM EST 2022 Aegis Virtual Conference on February 24, 2022 Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022 BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022. 2022 Aegis Virtual Conference – February 23-25, 2022 Date & Time: Thursday, March 24, 2:30 PM EST Presenter: Jonathan Solomon Conference registration: Link Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022 Date & Time: Tuesday, March 1, 8:30 AM EST Presenter: Conference registration: Jonathon Solomon Link Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022 Date & Time: Thursday, March 17, 2:00 PM EST Presenter: Jonathan Solomon Conference registration: Link Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website. About BiomX Inc. BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005117/en/Contacts BiomX Contacts Investor Relations: LifeSci Advisors, LLC John Mullaly (617)-698-9253 jmullaly@lifesciadvisors.com BiomX, Inc. Anat Primovich Corporate Project Manager +972 (50) 697-7228 anatp@biomx.com
2022 Aegis Virtual Conference on February 24, 2022 Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022. 2022 Aegis Virtual Conference – February 23-25, 2022 Date & Time: Thursday, March 24, 2:30 PM EST Presenter: Jonathan Solomon Conference registration: Link Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022 Date & Time: Tuesday, March 1, 8:30 AM EST Presenter: Conference registration: Jonathon Solomon Link Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022 Date & Time: Thursday, March 17, 2:00 PM EST Presenter: Jonathan Solomon Conference registration: Link Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website. About BiomX Inc. BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005117/en/
BiomX Contacts Investor Relations: LifeSci Advisors, LLC John Mullaly (617)-698-9253 jmullaly@lifesciadvisors.com BiomX, Inc. Anat Primovich Corporate Project Manager +972 (50) 697-7228 anatp@biomx.com